Tightening and anti-wrinkle composition as well as preparation method and application thereof

Abstract

The invention belongs to the technical field of cosmetics, and discloses a firming and anti-wrinkle composition as well as a preparation method and application thereof. The composition comprises the following components: kluyveromyces lactis / ganoderma sinensis fermentation product filtrate, sodium mannose phosphate and oligopeptide. Through the synergistic interaction of the kluyveromyces lactis / ganoderma sinensis fermentation product filtrate, the sodium mannose phosphate and the oligopeptide, the composition plays an inhibiting role in various aspects of skin laxity and aging from three key paths of enhancing cell viability, promoting tissue renewal and healing and promoting collagen generation; the aims of comprehensively and efficiently tightening and resisting wrinkles are fulfilled.

Description

Technical Field

[0001] The invention belongs to the technical field of cosmetics, and particularly relates to a firming and anti-wrinkle composition and a preparation method and application thereof. Background Art

[0002] Aging is a series of chronic, progressive degenerative changes in the morphological structure and physiological functions of organisms as they age. Aging is a natural law of life and an irreversible process that all organisms must go through. The external manifestations of skin aging are mainly: sagging skin, wrinkles, dryness and thinning, pigmentation, etc.; the internal manifestations are mainly weakened cell vitality, loss of collagen, damaged skin barrier, etc. Although skin aging is irreversible, targeted use of anti-aging cosmetics can play a certain delaying role.

[0003] Existing anti-aging cosmetics mainly focus on promoting collagen production. Although they have certain effects, their effects are relatively limited. To achieve better anti-aging effects, we need to start from the principles of skin aging and intervene in multiple causes of skin aging, such as improving cell vitality, repairing the skin barrier, and promoting collagen production, so as to better delay skin aging. Summary of the invention

[0004] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention provides a firming and anti-wrinkle composition and its preparation method and application, which inhibits various aspects of skin sagging and aging by enhancing cell vitality, promoting tissue renewal and healing, and promoting collagen production, thereby achieving comprehensive and efficient firming and anti-wrinkle purposes.

[0005] The first aspect of the present invention provides a composition comprising ingredients: Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, sodium mannose phosphate and oligopeptides.

[0006] Specifically, the lactic acid Kluyveromyces / Ganoderma lucidum fermentation product filtrate is obtained by fermenting Ganoderma lucidum extract with lactic acid Kluyveromyces. Most of the Ganoderma lucidum extracts currently on the market use Ganoderma lucidum as raw materials, and Ganoderma lucidum is rarely used. Ganoderma lucidum and Ganoderma lucidum have great differences in chemical composition. The main components of Ganoderma lucidum are highly oxidized lanosterol compounds, while Ganoderma lucidum is aromatic terpenes, ergosterols and alkaloid compounds. Ganoderma lucidum from different sources also has certain differences in its corresponding effects. The lactic acid Kluyveromyces / Ganoderma lucidum fermentation product filtrate used in the present invention can significantly promote COL-1 synthesis and reduce the generation of MMP-1, and has good firming and anti-wrinkle effects.

[0007] Specifically, sodium mannose phosphate participates in the material and energy metabolism process, provides the material and energy basis for biochemical processes, enhances cell vitality, and thus achieves anti-aging at the cellular level.

[0008] Specifically, oligopeptides can shorten the healing time of injuries, restore the skin barrier, repair broken and aged elastic fiber networks, thereby increasing firmness. They can tighten the skin, enhance skin elasticity, remove wrinkles and anti-aging effects.

[0009] Specifically, the firming and anti-wrinkle effects of the composition of the present invention are not achieved by randomly selecting and compounding several ingredients, but by in-depth research on the mechanism of action of skin barrier repair and firming and anti-wrinkle. After multiple research and experiments, three ingredients with corresponding effects, namely, lactic acid Kluyveromyces / Ganoderma lucidum fermentation product filtrate, sodium mannose phosphate and oligopeptides, are screened out from numerous ingredients. After compounding, they have a synergistic effect, and play an inhibitory effect on all aspects of skin sagging and aging from the three key pathways of enhancing cell vitality, promoting tissue renewal and healing, and promoting collagen production, thereby achieving comprehensive and efficient firming and anti-wrinkle purposes.

[0010] In some embodiments of the present invention, the composition comprises the following ingredients, measured by weight: 0.1-95 parts of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.003-0.15 parts of sodium mannose phosphate, and 0.0005-0.025 parts of oligopeptide.

[0011] In some embodiments of the present invention, the content of Ganoderma lucidum polysaccharide in the filtrate of the Kluyveromyces lactis / Ganoderma lucidum fermentation product is ≥1.5 mg / mL.

[0012] In some embodiments of the present invention, the oligopeptide includes at least one of oligopeptide-1, oligopeptide-2, oligopeptide-3, oligopeptide-4 and oligopeptide-5.

[0013] The second aspect of the present invention provides a method for preparing the composition according to the first aspect of the present invention, comprising the following steps:

[0014] The Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, sodium mannose phosphate and oligopeptides are mixed to obtain a composition.

[0015] The third aspect of the present invention provides an external skin preparation, wherein the external skin preparation comprises the composition according to the first aspect of the present invention.

[0016] In some embodiments of the present invention, the content of the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate in the external skin preparation is 0.1-95 wt %.

[0017] In some embodiments of the present invention, the content of sodium mannose phosphate in the external skin preparation is 0.003-0.15 wt %.

[0018] In some embodiments of the present invention, the content of the oligopeptide in the external skin preparation is 0.0005-0.025 wt %.

[0019] A fourth aspect of the present invention provides a cosmetic comprising the composition according to the first aspect of the present invention.

[0020] In some embodiments of the present invention, the content of the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate in the cosmetic is 0.1-95 wt %.

[0021] In some embodiments of the present invention, the content of sodium mannose phosphate in the cosmetic is 0.003-0.15 wt %.

[0022] In some embodiments of the present invention, the content of the oligopeptide in the cosmetic is 0.0005-0.025 wt %.

[0023] In some embodiments of the present invention, the cosmetic further comprises at least one of an emulsifier, a thickener, a moisturizer, a pH adjuster, a preservative and a fragrance.

[0024] In some embodiments of the present invention, the cosmetic comprises any one of lotion, essence, emulsion, cream or mask.

[0025] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0026] (1) The composition provided by the present invention, through the synergistic enhancement of the filtrate of Kluyveromyces lactis / Ganoderma lucidum fermentation product, sodium mannose phosphate and oligopeptides, exerts an inhibitory effect on various aspects of skin sagging and aging from the three key pathways of enhancing cell vitality, promoting tissue renewal and healing, and promoting collagen production, thereby achieving a comprehensive and efficient firming and anti-wrinkle purpose.

[0027] (2) The composition provided by the present invention is mild and non-irritating, can enhance cell vitality, promote COL-1 production, inhibit MMP-1 production, effectively increase the water content of the skin, reduce transepidermal water loss, enhance skin elasticity and firmness, reduce wrinkles, and has excellent moisturizing, repairing, firming and anti-wrinkle effects. DETAILED DESCRIPTION

[0028] In order to make the technical scheme of the present invention more clearly understood by those skilled in the art, the following embodiments are listed for illustration. It should be pointed out that the following embodiments do not limit the protection scope of the present invention.

[0029] Unless otherwise specified, the raw materials, reagents or devices used in the present invention can be obtained from conventional commercial channels or by existing known methods.

[0030] Example 1

[0031] A composition comprises the following components in parts by weight: 1 part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.04 part of sodium mannose phosphate, and 0.0025 part of oligopeptide-1.

[0032] Example 2

[0033] A composition comprises the following components in parts by weight: 5 parts of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.15 parts of sodium mannose phosphate, and 0.01 parts of oligopeptide-2.

[0034] Example 3

[0035] A composition comprises the following components in parts by weight: 95 parts of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.003 parts of sodium mannose phosphate, and 0.0005 parts of oligopeptide-3.

[0036] Example 4

[0037] A composition comprises the following components in parts by weight: 0.1 parts of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.003 parts of sodium mannose phosphate, and 0.025 parts of oligopeptide-4.

[0038] Example 5

[0039] A composition comprises the following components in parts by weight: 0.1 parts of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.15 parts of sodium mannose phosphate, and 0.0005 parts of oligopeptide-5.

[0040] Comparative Example 1

[0041] A composition comprises the following components in parts by weight: 1 part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate and 0.04 part of sodium mannose phosphate.

[0042] Comparative Example 2

[0043] A composition comprises the following components in parts by weight: 1 part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate and 0.0025 parts of oligopeptide-1.

[0044] Comparative Example 3

[0045] A composition comprises the following components in parts by weight: 0.04 parts of sodium mannose phosphate and 0.0025 parts of oligopeptide-1.

[0046] Comparative Example 4

[0047] 1 part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate.

[0048] Comparative Example 5

[0049] 0.04 parts of sodium mannose phosphate.

[0050] Comparative Example 6

[0051] Oligopeptide-1 0.0025 parts.

[0052] Comparative Example 7

[0053] A composition comprises the following components in parts by weight: 1 part of Ganoderma lucidum extract, 0.04 part of sodium mannose phosphate, and 0.0025 part of oligopeptide-1.

[0054] Comparative Example 8

[0055] A composition comprises the following components in parts by weight: 1 part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.04 part of sodium mannose phosphate, and 0.0025 part of acetyl hexapeptide-8.

[0056] Comparative Example 9

[0057] A composition comprises the following components in parts by weight: 1 part of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.04 part of beta-glucan, and 0.0025 part of oligopeptide-1.

[0058] Application Example 1

[0059] A firming and anti-wrinkle lotion comprises the composition of Example 1, and the formula is shown in Table 1.

[0060] Table 1

[0061]

[0062]

[0063] The preparation method is:

[0064] (1) Add the raw materials of phase A into a stirring pot in sequence, heat to 60°C, and stir to dissolve evenly;

[0065] (2) Heat the raw material of phase B to 60°C until it is dissolved and transparent, add it to a stirring pot and disperse it evenly, and then cool it to 40°C;

[0066] (3) Add the raw materials of phase C into a stirring pot and stir to disperse them evenly;

[0067] (4) After the raw materials of phase D are dispersed evenly, they are added into a stirring pot and dispersed evenly, and then the temperature is lowered to below 37°C to obtain a firming and anti-wrinkle lotion.

[0068] Application Example 2

[0069] A firming and anti-wrinkle facial mask comprising the composition of Example 1, with a formula as shown in Table 2.

[0070] Table 2

[0071]

[0072]

[0073] The preparation method is:

[0074] (1) Add the raw materials of phase A into a stirring pot in sequence, heat to 60°C, and stir to dissolve evenly;

[0075] (2) Add the raw materials of phase B into a stirring pot and homogenize and disperse them evenly;

[0076] (3) Heat the C phase raw material to 60°C until it is dissolved and transparent, add it to a stirring pot and disperse it evenly, and then cool it to 40°C;

[0077] (3) Add the raw materials of phase D into a stirring pot and stir to disperse them evenly;

[0078] (4) After the raw materials of phase E are dispersed evenly, they are added into a stirring pot and dispersed evenly, and then the temperature is lowered to below 37° C. to obtain a firming and anti-wrinkle mask.

[0079] Application Example 3

[0080] A firming and anti-wrinkle lotion comprises the composition of Example 1, and the formula is shown in Table 3.

[0081] Table 3

[0082]

[0083]

[0084] The preparation method is:

[0085] (1) Add the raw materials of phase A into an emulsifying pot in sequence, heat to 80°C, and stir to dissolve evenly;

[0086] (2) Add the raw materials of phase B to the oil phase pot in sequence, heat to 80°C, stir and disperse evenly, then add to the emulsification pot, homogenize and emulsify, stir evenly and then cool to 60°C;

[0087] (3) Add the raw materials of phase C into the emulsifier and homogenize and disperse them evenly;

[0088] (4) Heat the phase D raw material to 60°C until it is dissolved and transparent, add it to the emulsifier and disperse it evenly, and then cool it to 40°C;

[0089] (5) After the raw materials of phase E are dispersed evenly, they are added into an emulsifying pot and dispersed evenly, and then the temperature is lowered to below 37° C. to obtain a firming and anti-wrinkle emulsion.

[0090] Application Example 4

[0091] A firming and anti-wrinkle cream comprises the composition of Example 1, and the formula is shown in Table 4.

[0092] Table 4

[0093]

[0094]

[0095] The preparation method is:

[0096] (1) Add the raw materials of phase A into an emulsifying pot in sequence, heat to 80°C, and stir to dissolve evenly;

[0097] (2) Add the raw materials of phase B to the oil phase pot in sequence, heat to 80°C, stir and disperse evenly, then add to the emulsification pot, homogenize and emulsify, stir evenly and then cool to 60°C;

[0098] (3) Add the raw materials of phase C into the emulsifier and homogenize and disperse them evenly;

[0099] (4) Heat the phase D raw material to 60°C until it is dissolved and transparent, add it to the emulsifier and disperse it evenly, and then cool it to 40°C;

[0100] (5) After the raw materials of phase E are dispersed evenly, they are added into an emulsifying pot and dispersed evenly, and then the temperature is lowered to below 37° C. to obtain a firming anti-wrinkle cream.

[0101] Comparative application example 1

[0102] The difference from Application Example 4 is that the cream of Comparative Application Example 1 does not contain the composition of Example 1, that is, it lacks the filtrate of Kluyveromyces lactis / Ganoderma lucidum fermentation product, sodium mannose phosphate and oligopeptide-1, and the remaining raw materials, contents and preparation methods are the same as those of Application Example 4.

[0103] Comparative Application Example 2

[0104] The difference from Application Example 4 is that the cream of Application Example 2 replaces the composition of Example 1 with the composition of Comparative Example 1, i.e., lacks oligopeptide-1, and the remaining raw materials, contents and preparation methods are the same as those of Application Example 4.

[0105] Comparative Application Example 3

[0106] The difference from Application Example 4 is that the cream of Application Example 3 replaces the composition of Example 1 with the composition of Comparative Example 2, i.e. sodium mannose phosphate is missing, and the remaining raw materials, contents and preparation methods are the same as those of Application Example 4.

[0107] Comparative Application Example 4

[0108] The difference from Application Example 4 is that the cream of Application Example 4 replaces the composition of Example 1 with the composition of Comparative Example 3, i.e., lacks the filtrate of Kluyveromyces lactis / Ganoderma lucidum fermentation product, and the remaining raw materials, contents and preparation methods are the same as those of Application Example 4.

[0109] Comparative Application Example 5

[0110] The difference from Application Example 4 is that the cream of Application Example 5 replaces the composition of Example 1 with the ingredients of Comparative Example 4, i.e., sodium mannose phosphate and oligopeptide-1 are missing, and the remaining raw materials, contents and preparation methods are the same as those of Application Example 4.

[0111] Comparative Application Example 6

[0112] The difference from Application Example 4 is that the cream of Comparative Example 6 replaces the composition of Example 1 with the ingredients of Comparative Example 5, i.e., lacks the lactic acid Kluyveromyces / Ganoderma lucidum fermentation product filtrate and oligopeptide-1, and the remaining raw materials, contents and preparation methods are the same as those of Application Example 4.

[0113] Comparative Application Example 7

[0114] The difference from Application Example 4 is that the cream of Comparative Application Example 7 replaces the composition of Example 1 with the ingredients of Comparative Example 6, i.e., lacks the lactic acid Kluyveromyces / Ganoderma lucidum fermentation product filtrate and sodium mannose phosphate, and the remaining raw materials, contents and preparation methods are the same as those of Application Example 4.

[0115] Comparative Application Example 8

[0116] The difference from Application Example 4 is that the cream of Comparative Example 8 replaces the composition of Example 1 with the composition of Comparative Example 7, that is, an equal amount of the filtrate of the lactic acid Kluyveromyces / Ganoderma lucidum fermentation product is replaced with Ganoderma lucidum extract, and the remaining raw materials, contents and preparation methods are the same as those in Application Example 4.

[0117] Comparative Application Example 9

[0118] The difference from Application Example 4 is that the cream of Comparative Example 9 replaces the composition of Example 1 with the composition of Comparative Example 8, that is, an equal amount of oligopeptide-1 is replaced with acetyl hexapeptide-8, and the remaining raw materials, contents and preparation methods are the same as those of Application Example 4.

[0119] Comparative Application Example 10

[0120] The difference from Application Example 4 is that the cream of Comparative Example 10 replaces the composition of Example 1 with the composition of Comparative Example 9, that is, an equal amount of sodium mannose phosphate is replaced with β-glucan, and the remaining raw materials, contents and preparation methods are the same as those of Application Example 4.

[0121] Test Example 1 Red blood cell hemolysis test

[0122] The red blood cell hemolysis test is one of the alternative methods to the rabbit eye irritation test (Draize test). The basic principle is to evaluate the damage of chemicals to eye tissue cells by measuring the amount of hemoglobin dissolved and the degree of denaturation. Internationally, the RBC test is mainly used to evaluate the eye irritation of chemicals such as cosmetics and raw materials.

[0123] The compositions of Examples 1-5 and the compositions or components of Comparative Examples 1-9 were subjected to a red blood cell hemolysis test, which was conducted in accordance with the RBC test method and grading standards of the European Center for Validation of Alternative Methods (ECVAM). The ECVAM cosmetic product RBC test irritation grading standards are shown in Table 5.

[0124] Table 5

[0125]

[0126]

[0127] The results of the red blood cell hemolysis experiment are shown in Table 6, where L / D is the ratio of HD50 to DI, where HD50 is the sample concentration when 50% of the red blood cells are hemolyzed, and DI is the protein denaturation index.

[0128] Table 6

[0129] Sample name evaluate Example 1 Non-irritating Example 2 Non-irritating Example 3 Non-irritating Example 4 Non-irritating Example 5 Non-irritating Comparative Example 1 Non-irritating Comparative Example 2 Non-irritating Comparative Example 3 Non-irritating Comparative Example 4 Non-irritating Comparative Example 5 Non-irritating Comparative Example 6 Non-irritating Comparative Example 7 Slightly irritating Comparative Example 8 Non-irritating Comparative Example 9 Non-irritating

[0130] From the red blood cell hemolysis test results in Table 6, it can be seen that, except for comparative example 7 which is slightly irritating, Examples 1-5 and comparative examples 1-6 and 8-9 are all non-irritating, indicating that the compositions of the present invention are mild and non-irritating.

[0131] Test Example 2: Determination of senescence-associated β-galactosidase (SA-β-gal)

[0132] Human dermal fibroblasts (HDF) were cultured in 6-well plates at 1 × 10 4 The cells were cultured at a density of 10 cells / mL at 37°C and 5% CO2 for 24 hours. After HDFs were treated with the sample (5%) for 24 hours, they were washed twice with phosphate-buffered saline (PBS) and heated at 30 J / cm 2UVB irradiation. Then, PBS was removed, and HDF was cultured with the sample (5%) at 37°C and 5% CO2 for 24 hours. Washed with 1 ml of PBS, 0.5 ml of fixative was added, and then left at room temperature for 15 minutes to fix. 0.5 mL of mixed staining solution (470 μL of staining solution, 5 μL of staining supplement, and 25 μL of dimethylformamide containing 20 mg / mL X-gal) was added to the fixed HDF, and the cells were stained by incubation at 37°C for 24 hours. Then, the stained cells were washed with PBS, and 500 fibroblasts were randomly selected from each sample plate for photography under a microscope, and the SA-β-Gal-stained fibroblasts were counted.

[0133] Relative ratio of senescent cells = number of senescent cells in the sample / number of senescent cells in the model group × 100%.

[0134] The compositions of Examples 1-5 and the compositions or components of Comparative Examples 1-9 were tested, and the results are shown in Table 7.

[0135] Table 7

[0136]

[0137]

[0138] It can be seen from the data in Table 7 that the relative ratios of senescent cells in the compositions of Examples 1-5 are all below 53%, and the corresponding ratios of Comparative Examples 1-9 are all above 60%, indicating that the composition of the present invention has a good effect of improving cell viability, and the components in the composition have a synergistic effect, which can exert a better effect.

[0139] Experimental Example 3 Analysis of human type I collagen and matrix metalloproteinases

[0140] HDFs were plated in 6-well plates at 2 × 10 4 The cells were cultured at a density of 10 cells / mL at 37°C and 5% CO2 for 24 hours. After HDFs were treated with the sample (5%) for 24 hours, HDFs were washed twice with PBS and heated at 30 J / cm 2 Then, the PBS was removed and the HDF was cultured with the sample (5%) at 37°C and 5% CO2 for 24 hours. After the culture, the contents of human type I collagen (COL-I) and matrix metalloproteinase-1 (MMP-1) were determined according to the ELISA kit operating method.

[0141] The compositions of Examples 1-5 and the compositions or components of Comparative Examples 1-9 were used to determine the contents of human type I collagen and matrix metalloproteinases. The results are shown in Table 8.

[0142] Table 8

[0143]

[0144]

[0145] It is understandable that the higher the COL-1 content, the lower the MMP-1 content, which means that the ability to promote collagen production is stronger and the corresponding firming and anti-wrinkle ability is also stronger.

[0146] From the results in Table 8, it can be seen that the COL-1 content and MMP-1 content corresponding to each embodiment are better than those of Comparative Examples 1-9, indicating that the composition of the present invention has higher firming and anti-wrinkle ability, and the components in the composition have a synergistic effect.

[0147] Test Example 4 Human Transepidermal Water Loss Test

[0148] 110 healthy subjects were selected and randomly divided into 11 groups, with 10 subjects in each group. Application Example 4 and Comparative Application Examples 1-10 were used as test samples. The subjects used the samples on their faces once in the morning and once in the evening every day. A Corneometer CM825 skin moisture tester and an AF200 skin moisture loss tester were used. Before use (D0) and on the 28th day (D28) of use, at a temperature of 21±1°C and a humidity of 50±10%, the subjects cleaned their faces and waited for 20 minutes, then the facial moisture content and transepidermal water loss (TEWL) were measured respectively, and the corresponding change rates were calculated to comprehensively evaluate the moisturizing and repairing effects of the products on human skin. The results are shown in Table 9.

[0149] Table 9

[0150]

[0151]

[0152] It is understandable that the higher the water content change rate, the better the moisturizing ability, and the greater the reduction in TEWL change rate, the better the repair ability.

[0153] It can be seen from the results in Table 9 that, compared with comparative application examples 1-10, application example 4 shows better effects in terms of both water content and transepidermal water loss, indicating that the cosmetics containing the composition of the present invention have better moisturizing and repairing effects.

[0154] Test Example 5 Human body firming effect test

[0155] 110 healthy subjects were selected and randomly divided into 11 groups, with 10 people in each group. Application Example 4 and Comparative Application Examples 1-10 were used as test samples. The subjects used the samples on their faces once in the morning and once in the evening every day. Cutometer dual MPA580 skin elasticity tester was used. Before use (D0) and on the 28th day (D28) of use, at a temperature of 21±1°C and a humidity of 50±10%, the subjects cleaned their faces and waited for 20 minutes, then measured the facial elasticity-F4 value and elasticity-R2 value, and calculated the change rates of the F4 value and the R2 value, and comprehensively evaluated the firming effect of the product on human skin. The results are shown in Table 10.

[0156] Table 10

[0157]

[0158]

[0159] It can be understood that the F4 value and the R2 value represent the firmness and elasticity of the skin respectively. The more the F4 value change rate decreases and the more the R2 value change rate increases, the better the skin firmness and elasticity.

[0160] From the results in Table 10, it can be seen that the values ​​of the sample using Application Example 4 are better than those of Comparative Application Examples 1-10, indicating that the cosmetics containing the composition of the present invention have a better firming effect.

[0161] Test Example 6: Human Anti-wrinkle Effect Test

[0162] 110 healthy subjects were selected and randomly divided into 11 groups, with 10 subjects in each group. Application Example 4 and Comparative Application Examples 1-10 were used as test samples. The subjects used the samples on their faces once in the morning and once in the evening every day. Using VISIA 7 image analyzer, before use (D0) and on the 28th day (D28) of use, at a temperature of 21±1°C and a humidity of 50±10%, the subjects cleaned their faces and waited for 20 minutes, then measured the number of wrinkles and the total area of ​​wrinkles, and calculated the corresponding change rate, and comprehensively evaluated the anti-wrinkle effect of the product on human skin. The results are shown in Table 11.

[0163] Table 11

[0164]

[0165]

[0166] From the results in Table 11, it can be seen that the degree of reduction in the wrinkle number change rate and the total wrinkle area change rate corresponding to the sample using Application Example 4 is higher than that of Comparative Application Examples 1-10, indicating that its anti-wrinkle ability is better.

[0167] In summary, the composition of the present invention is mild and non-irritating, and its moisturizing, repairing, firming, anti-wrinkle and other effects are better than those of the control group lacking any one or two ingredients, or replaced with similar functional ingredients. This shows that the composition of the present invention is reasonably matched, has a synergistic effect, and can significantly improve the moisturizing, repairing, firming and anti-wrinkle effects.

[0168] The preferred embodiments of the present invention are described in detail above, but the invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.

Claims

1. A composition, characterized in that The composition comprises the following ingredients: lactic acid Kluyveromyces / Ganoderma lucidum fermentation product filtrate, sodium mannose phosphate and oligopeptides.

2. The composition according to claim 1, characterized in that The composition comprises the following components in parts by mass: 0.1-95 parts of Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, 0.003-0.15 parts of sodium mannose phosphate and 0.0005-0.025 parts of oligopeptide.

3. The composition according to claim 1, characterized in that The ganoderma lucidum polysaccharide content in the filtrate of the Kluyveromyces lactis / Ganoderma lucidum fermentation product is ≥1.5 mg / mL.

4. A method for preparing the composition according to any one of claims 1 to 3, characterized in that: The following steps are involved: The Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate, sodium mannose phosphate and oligopeptides are mixed to obtain a composition.

5. A skin preparation for external use, characterized in that: The external skin preparation comprises the composition according to any one of claims 1 to 3.

6. The external skin preparation according to claim 5, characterized in that The content of the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate is 0.1-95wt%, the content of the sodium mannose phosphate is 0.003-0.15wt%, and the content of the oligopeptide is 0.0005-0.025wt%.

7. A cosmetic, characterized in that: The cosmetic comprises the composition according to any one of claims 1 to 3.

8. The cosmetic according to claim 7, characterized in that: The content of the Kluyveromyces lactis / Ganoderma lucidum fermentation product filtrate is 0.1-95wt%, the content of the sodium mannose phosphate is 0.003-0.15wt%, and the content of the oligopeptide is 0.0005-0.025wt%.

9. The cosmetic according to claim 7, characterized in that: The cosmetic further comprises at least one of an emulsifier, a thickener, a moisturizer, a pH adjuster, a preservative and a fragrance.

10. The cosmetic according to claim 7, characterized in that: The cosmetics include any one of lotion, essence, emulsion, cream or facial mask.

Images